New York, June 19, 2026, 09:06 (EDT)
- Pfizer shares slipped 2.7% to end at $25.21 on Thursday. U.S. stock markets were closed for the Juneteenth holiday.
- Pfizer said CFO Dave Denton is stepping down Aug. 15. Cecile Guegan will take over as interim CFO starting Aug. 16 as the company looks for Denton’s permanent replacement.
- Investors next week are looking to see if the change is seen as business as usual or a sign of more uncertainty for Pfizer’s post-COVID outlook.
Pfizer dropped 2.7% to $25.21 Thursday, closing out a short week lower after its CFO said he is leaving. The news raised questions about Pfizer’s 2026 outlook and its post-pandemic turnaround. U.S. markets shut Friday for Juneteenth.
That’s what investors head into next week with. Pfizer isn’t only swapping finance chiefs; the company is making the change as it works to prove its deals, cuts, and fresh drugs are enough to offset weaker COVID vaccine and antiviral demand.
Pfizer CFO Dave Denton will leave the company on Aug. 15. He plans to move to a job in the consumer-goods sector, outside pharma. Cecile Guegan, who is SVP of finance for the global biopharma unit, will take over as interim CFO starting Aug. 16. Pfizer said it would search internally and externally for a permanent replacement.
Denton told Pfizer on June 16 he will leave, according to a filing. He said the move was not because of the company’s finances or its accounting, reporting, or operations, and there was no disagreement over policies. That’s key. It narrows the bear case, though the succession question stays in play.
Pfizer lagged behind as the S&P 500 added 1.08% Thursday. Pfizer fell 2.48%, worse than Johnson & Johnson and Eli Lilly, which slipped 2.48% and 1.21% each. Volume soared to roughly 119.4 million, way above the 50-day average of 34.8 million shares.
Pfizer (PFE) is down 3.8% for the week through Thursday, slipping from its June 12 close at $26.21. With the next week coming up, investors are focused less on Thursday’s selling and more on whether Pfizer can keep its message steady on capital allocation and guidance when markets open Monday. Any sign of an orderly finance handoff will be watched.
Chief Executive Albert Bourla called Denton a “steady and trusted steward” and said he had “every confidence” in Guegan. Denton said Pfizer is “in excellent hands.” The companies aimed to show things were under control with these statements, and to some extent it came across that way. Shares still fell. Business Wire
Scotiabank analyst Louise Chen said Denton’s departure is fueling investor worry about Pfizer’s 2026 outlook, leadership changes and the timing, as Pfizer gets ready for a push into obesity drugs. On a different note, J.P. Morgan’s Chris Schott wrote last month that investors need to see more clinical data and less risk in Pfizer’s pipeline before sentiment turns.
Pfizer stuck to its 2026 outlook, keeping its sales target at $59.5 billion to $62.5 billion and adjusted diluted EPS between $2.80 and $3.00. Adjusted EPS strips out certain items from profit per share. First-quarter sales reached $14.5 billion, up 2% operationally. Sales from launched and acquired products jumped 22% on the same basis.
Obesity is the focus. Pfizer wants into a market where Eli Lilly has set the tone for investors, but Reuters says Pfizer’s first obesity drug from its $10 billion Metsera deal wouldn’t hit shelves until 2028 at the earliest, if trials work out. That leaves Pfizer with some runway, but also exposes it to early market disappointment if timelines slip.
The risk case isn’t hard to see. A long hunt for a new CFO, softer trial results, stricter regulation, or pricing pressure could all keep shares stuck—so could missing out on expected gains from the Seagen or Metsera deals. Pfizer flagged uncertainty in R&D, rivals, regulation, and deal execution as potential reasons why real results might not match its outlook.
